Immunotherapy in Older Patients with Cancer: A Narrative Review

References

• D’Errico G, Machado HL, Sainz B. A current perspective on cancer immune therapy: step‐by‐step approach to constructing the magic bullet. Clin Transl Med. 2017;6(1). doi:10.1186/s40169-016-0130-5
   PubMedGoogle Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Cancer of any site - cancer stat facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/all.html. Accessed November 26, 2021.
   Google Scholar
• Cancer today. Estimated number of new cases in 2020, World, Both sexes, ages 65+. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=13&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1. Accessed November 26, 2021.
   Google Scholar
• Cancer Tomorrow. Changes of new cases from 2020 to 2030, Both sexes, age (65-85+). Available from: https://gco.iarc.fr/tomorrow/en/dataviz/bars?mode=population&years=2030&age_start=13&key=percent&show_bar_mode_prop=0. Accessed November 26, 2021.
   Google Scholar
• Elkrief A, Richard C, Malo J, et al. Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: real-world data from multicentric cohorts in Canada and France. J Geriatr Oncol. 2020;11(5):802–806. doi:10.1016/j.jgo.2020.01.002
   PubMed Web of Science ®Google Scholar
• Abraham G, Jobanputra K, Noronha V, et al. Immune checkpoint inhibitors in older patients with solid tumors: real-world experience from India. Cancer Res Stat Treat. 2021;4(2):270–276. doi:10.4103/crst.crst_86_21
   Google Scholar
• Betof AS, Nipp RD, Giobbie‐Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. oncologist. 2017;22(8):963–971. doi:10.1634/theoncologist.2016-0450
   PubMed Web of Science ®Google Scholar
• Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018;6(1):26. doi:10.1186/s40425-018-0336-8
   PubMed Web of Science ®Google Scholar
• Singh H, Kanapuru B, Smith C, et al.; Food and Drug Administration. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. J Clin Oncol. 2017;35(15_suppl):10009. doi:10.1200/JCO.2017.35.15_suppl.10009
   Google Scholar
• Abraham G, Jobanputra KN, Noronha V, et al. Immune checkpoint inhibitors in older patients with solid tumors: real-world experience from India. Cancer Res Stat Treat. 2021;4(2):270. doi:10.4103/crst.crst_86_21
   Google Scholar
• Hermansen CK, Donskov F. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: older patients more prone to toxicity. J Geriatr Oncol. 2021;12(5):827–833. doi:10.1016/j.jgo.2020.12.008
   PubMed Web of Science ®Google Scholar
• Granier C, Gey A, Roncelin S, Weiss L, Paillaud E, Tartour E. Immunotherapy in older patients with cancer. Biomed J. 2021;44(3):260–271. doi:10.1016/j.bj.2020.07.009
   PubMed Web of Science ®Google Scholar
• Godby RC, Johnson DB, Williams GR. Immunotherapy in Older Adults with Cancer. Curr Oncol Rep. 2019;21(7):56. doi:10.1007/s11912-019-0806-2
   PubMed Web of Science ®Google Scholar
• Sun YM, Wang Y, Sun XX, Chen J, Gong ZP, Meng HY. Clinical efficacy of immune checkpoint inhibitors in older non-small-cell lung cancer patients: a meta-analysis. Front Oncol. 2020;10:558454. doi:10.3389/fonc.2020.558454
   PubMedGoogle Scholar
• Ron DA, Manrique MAA, Martínez JM, et al. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: a subgroup analysis of the Galician lung cancer group. J Geriatr Oncol. 2020. doi:10.1016/j.jgo.2020.11.010
   Web of Science ®Google Scholar
• Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of age on outcomes with immunotherapy in patients with non–small cell lung cancer. J Thorac Oncol. 2019;14(3):547–552. doi:10.1016/j.jtho.2018.11.011
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Perier-Muzet M, Gatt E, Péron J, et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82. doi:10.1001/jamadermatol.2017.4584
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bartlett NL, LaPlant B et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. The Lancet: Haematology. 2020;7(11):e808–e815 . doi:10.1016/S2352-3026(20)30275-1
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the Phase II CHECKMATE 205 study. J Clin Oncol off J Am Soc Clin Oncol. 2019;37(23):1997–2007. doi:10.1200/JCO.19.00315
   PubMed Web of Science ®Google Scholar
• Connors JM. Immunotherapy for older patients with classic Hodgkin lymphoma. Lancet Haematol. 2020;7(11):e776. doi:10.1016/S2352-3026(20)30321-5
   PubMed Web of Science ®Google Scholar
• Jodon G, Fischer S, Kessler ER. Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors. Drugs Aging. 2018;35(5):409–421. doi:10.1007/s40266-018-0540-8
   PubMed Web of Science ®Google Scholar
• Nishiyama N, Kobayashi T, Narita S, et al. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J Geriatr Oncol. 2022;13(1):88–93. doi:10.1016/j.jgo.2021.07.002
   PubMed Web of Science ®Google Scholar
• Samani A, Zhang S, Spiers L, et al. Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer. 2020;8(2):e000871. doi:10.1136/jitc-2020-000871
   PubMed Web of Science ®Google Scholar
• Herin H, Castanon E, Dyevre V, et al. Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: the Gustave Roussy experience. Ann Oncol. 2017;28:v413. doi:10.1093/annonc/mdx376.028
   Google Scholar
• US Food and Drug Administration (FDA) . Oncology (Cancer) / Hematologic malignancies approval notifications. FDA; 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Accessed January 5, 2022.
   Google Scholar
• Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017;8(3):229–235. doi:10.1016/j.jgo.2017.02.001
   PubMed Web of Science ®Google Scholar
• Friedman CF, Horvat TZ, Minehart J, et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). J Clin Oncol. 2016;34(15_suppl):10009. doi:10.1200/JCO.2016.34.15_suppl.10009
   Web of Science ®Google Scholar
• Paz-Ares L, Urban L, Audigier-Valette C, et al. P1.01-79 CheckMate 817: safety of flat-dose nivolumab plus weight-based ipilimumab for the first-line (1L) treatment of advanced NSCLC. J Thorac Oncol. 2018;13(10):S493. doi:10.1016/j.jtho.2018.08.635
   Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. PMID: 27827313. doi:10.1158/1078-0432.CCR-16-1741
   PubMed Web of Science ®Google Scholar
• Yancik R. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31(2):128–136. doi:10.1053/j.seminoncol.2003.12.024
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138
   PubMed Web of Science ®Google Scholar
• Marrone KA, Forde PM. Cancer immunotherapy in older patients. Cancer J Sudbury Mass. 2017;23(4):219–222. doi:10.1097/PPO.0000000000000268
   PubMed Web of Science ®Google Scholar
• Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol. 1992;90(2):351–354. doi:10.1111/j.1365-2249.1992.tb07954.x
   PubMed Web of Science ®Google Scholar
• Apoil PA, Puissant-Lubrano B, Congy-Jolivet N, et al. Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults. Cell Immunol. 2017;314:42–53. doi:10.1016/j.cellimm.2017.02.001
   PubMed Web of Science ®Google Scholar
• Krichevsky S, Pawelec G, Gural A, et al. Age related microsatellite instability in T cells from healthy individuals. Exp Gerontol. 2004;39(4):507–515. doi:10.1016/j.exger.2003.12.016
   PubMed Web of Science ®Google Scholar
• Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today. 2000;21(10):515–521. doi:10.1016/s0167-5699(00)01714-x
   PubMedGoogle Scholar
• Shurin MR, Shurin GV, Chatta GS. Aging and the Dendritic cell system: implications for cancer. Crit Rev Oncol Hematol. 2007;64(2):90–105. doi:10.1016/j.critrevonc.2007.03.002
   PubMed Web of Science ®Google Scholar
• Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. 2013;12(4):1069–1078. doi:10.1016/j.arr.2013.04.003
   PubMed Web of Science ®Google Scholar
• Facchini A, Mariani E, Mariani AR, Papa S, Vitale M, Manzoli FA. Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing. Clin Exp Immunol. 1987;68(2):340–347.
   PubMed Web of Science ®Google Scholar
• Rukavina D, Laskarin G, Rubesa G, et al. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood. 1998;92(7):2410–2420. doi:10.1182/blood.V92.7.2410
   PubMed Web of Science ®Google Scholar
• Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. J Leukoc Biol. 2004;76(2):291–299. doi:10.1189/jlb.1103592
   PubMed Web of Science ®Google Scholar
• Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J Immunol. 2006;176(11):6586–6593. doi:10.4049/jimmunol.176.11.6586
   PubMed Web of Science ®Google Scholar
• Grizzle WE, Xu X, Zhang S, et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev. 2007;128(11–12):672–680. doi:10.1016/j.mad.2007.10.003
   PubMed Web of Science ®Google Scholar
• Fülöp T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Investig Clin Organo Hosp Enfermedades Nutr. 2016;68(2):84–91.
   PubMedGoogle Scholar
• Baitsch L, Baumgaertner P, Devêvre E, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350–2360. doi:10.1172/JCI46102
   PubMed Web of Science ®Google Scholar
• Yildiz B, Acar R. Immunotherapy in geriatric patients with advanced cancer. Eurasian J Med Oncol. 2020;4(3):209–214. doi:10.14744/ejmo.2020.44446
   Google Scholar
• Yang Y, Jin G, Pang Y, et al. Comparative efficacy and safety of nivolumab and nivolumab plus ipilimumab in advanced cancer: a systematic review and meta-analysis. Front Pharmacol. 2020;11:40. doi:10.3389/fphar.2020.00040
   PubMed Web of Science ®Google Scholar
• Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag. 2019;15:211–221. doi:10.2147/TCRM.S193338
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527. doi:10.1200/JCO.19.00934
   PubMed Web of Science ®Google Scholar
• Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. J Geriatr Oncol. 2019;10(3):411–414. doi:10.1016/j.jgo.2018.07.015
   PubMed Web of Science ®Google Scholar
• Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book. 2018;38. doi:10.1200/EDBK_201435
   PubMedGoogle Scholar
• Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer. Medicine. 2018;97(33):e11936. doi:10.1097/MD.0000000000011936
   PubMed Web of Science ®Google Scholar
• Alkharabsheh O, Kannarkatt P, Kannarkatt J, Karapetyan L, Laird-Fick HS, Al-Janadi A. An overview of the toxicities of checkpoint inhibitors in older patients with cancer. J Geriatr Oncol. 2018;9(5):451–458. doi:10.1016/j.jgo.2018.02.002
   PubMed Web of Science ®Google Scholar
• Elias R, Morales J, Rehman Y, Khurshid H. Immune Checkpoint Inhibitors in Older Adults. Curr Oncol Rep. 2016;18(8):47. doi:10.1007/s11912-016-0534-9
   PubMed Web of Science ®Google Scholar
• Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2018(2):CD011123. doi:10.1002/14651858.CD011123.pub2
   Google Scholar
• Canouï‐Poitrine F, Lièvre A, Dayde F, et al. Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort survey. oncologist. 2019;24(12):e1351–e1359. doi:10.1634/theoncologist.2019-0166
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Vos AG, Smorenburg CH, de Rooij SE, van Munster BC. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. oncologist. 2012;17(11):1439–1449. doi:10.1634/theoncologist.2012-0186
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(24):2595–2603. doi:10.1200/JCO.2013.54.8347
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465. doi:10.1200/JCO.2011.34.7625
   PubMed Web of Science ®Google Scholar
• Van holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging. 2019;36(10):927–938. doi:10.1007/s40266-019-00697-2
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, Longo DL. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7(5):325–333. doi:10.1016/j.jgo.2016.05.007
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923
   PubMed Web of Science ®Google Scholar